Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
about
ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatinHNF-1β in ovarian carcinomas with serous and clear cell change.DNA copy numbers profiles in affinity-purified ovarian clear cell carcinomaRsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor developmentSomatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinomaPrognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients.Ovarian clear cell adenocarcinoma: a continuing enigmaMethoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases.PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group.Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
P2860
Q28468340-FC0734D4-FE5C-4187-8F47-A0F8DBD3D24EQ33647555-F8C03CAA-389F-4104-9879-8878EAB937CEQ33767047-F6C9CF65-4031-4A4F-92A0-41DE212DE9A1Q34643587-A145596E-C508-43F2-A811-1FD7CD81A5B4Q34771886-FB1F2ECE-78B6-41AF-B989-6D84615BF887Q35057812-C14A8929-2193-4937-801A-BB17488C1D10Q35475560-D3A53318-A9D0-4B0A-AF93-9B5D41386075Q35612005-614DC3CD-84DE-4A83-80F3-44ECB6589C24Q35694661-8D390033-8B5E-4B57-B05E-7C37B2603BE6Q36026090-499BF19D-507D-4261-A0AD-02984FA3EE9EQ36361670-AB8375D7-6A8C-4A7F-855A-7BB370A4C64BQ36469640-61BD3DC4-1A8C-417E-A40C-83BF746E369EQ36608043-BE941E14-CF47-466B-BC70-9C8C83CA6BCBQ37123500-B318D49B-BE8D-4007-B10C-BEDBFBF844DEQ37346570-FB5C740D-3591-456B-A76C-68F80D1C271AQ37776738-BEBD8A47-8B9B-4E36-BF1A-A03638917CDAQ38013767-C00D6D1A-1E89-479F-9774-D325185C8D2EQ38168731-7FBC8126-DBF1-42A8-B02F-C6E7BDC228A7Q38183430-0E876940-297F-4357-8A9A-DCD764FC83DCQ43414877-8701137C-3586-4CDF-8104-B89399BB33F2Q43883837-F1F35694-D681-446C-AB18-CA618E6BCD11Q53280611-82FF6DC5-6803-4ECE-9057-F1F82210A1A6Q53517417-9A6D2E66-85B8-4C54-9526-423735F0701FQ54334674-C35640A6-D610-468A-8135-798E62F46235Q54360869-E05AA532-019D-40ED-90DD-E56A3A14EE35Q55452757-39B560FF-6F21-428D-916D-74D7DFA5C55D
P2860
Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@en
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@nl
type
label
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@en
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@nl
prefLabel
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@en
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@nl
P2093
P356
P1476
Long-term follow-up and progno ...... l adenocarcinoma of the ovary.
@en
P2093
Fumitaka Kikkawa
Hiroaki Kajiyama
Kazuhiko Ino
Kiyosumi Shibata
Michiyasu Kawai
Mika Mizuno
Seiji Nomura
Tetsuro Nagasaka
P304
P356
10.1002/JSO.20251
P577
2006-08-01T00:00:00Z